Azenta (NASDAQ: AZTA) insider transactions
In the twelve months to 10 November 2026, executives and directors of Azenta reported 0 open-market sales and 2 open-market purchases of 10,335 shares ($171,897), by 2 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 22 October 2026 | Madaus Martin D | Interim CEO | Shares withheld for tax | −1,294 | $36.01 | 41,308 | Form 4 |
| 22 September 2026 | Madaus Martin D | Interim CEO | Shares withheld for tax | −1,456 | $34.28 | 42,602 | Form 4 |
| 15 September 2026 | Bello Erik J. | VP Chief Accounting Officer | Grant or award | +4,586 | — | 4,586 | Form 4 |
| 14 September 2026 | Starr Ephraim | SVP, Gen Counsel & Secretary | Grant or award | +15,272 | — | 84,000 | Form 4 |
| 14 September 2026 | Lin Lawrence Y. | EVP, CFO and Treasurer | Grant or award | +30,544 | — | 110,199 | Form 4 |
| 14 September 2026 | Pirogova Olga | SVP and CHRO | Grant or award | +15,272 | — | 47,225 | Form 4 |
| 14 September 2026 | Martin William E. Iii | President Multiomics | Grant or award | +15,272 | — | 33,062 | Form 4 |
| 14 September 2026 | Madaus Martin D | Interim CEO | Grant or award | +36,653 | — | 44,058 | Form 4 |
| 9 August 2026 | Pirogova Olga | SVP and CHRO | Shares withheld for tax | −1,085 | $32.04 | 31,953 | Form 4 |
| 31 July 2026 | Starr Ephraim | SVP, Gen Counsel & Secretary | Open-market purchase | +335 | $24.17 | 68,728 | Form 4 |
| 18 May 2026 | Cornog William L | Director | Open-market purchase | +10,000 | $16.38 | 19,703 | Form 4 |
| 15 May 2026 | Starr Ephraim | SVP, Gen Counsel & Secretary | Shares withheld for tax | −3,621 | $16.02 | 68,393 | Form 4 |
| 28 April 2026 | Martin William E. Iii | President Multiomics | Grant or award | +17,790 | $24.24 | 17,790 | Form 4 |
| 6 February 2026 | Nova Tina Susan | Director | Grant or award | +5,663 | $27.85 | 15,772 | Form 4 |
| 5 February 2026 | Koffey Quentin | Director | Grant or award | +5,663 | — | 10,698 | Form 4 |
| 5 February 2026 | McLaughlin Erica | Director | Grant or award | +5,663 | $27.85 | 22,521 | Form 4 |
| 5 February 2026 | Casal Frank | Director | Grant or award | +7,243 | $27.85 | 21,803 | Form 4 |
| 5 February 2026 | Doshi Dipal | Director | Grant or award | +5,663 | $27.85 | 9,703 | Form 4 |
| 24 November 2025 | Starr Ephraim | SVP, Gen Counsel & Secretary | Grant or award | +34,235 | — | 72,014 | Form 4 |
| 24 November 2025 | Zhou Ginger | SVP and GM, Multiomics | Grant or award | +13,042 | — | 38,755 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Azenta page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.